Sanara MedTech Inc.

Good day, ladies and gentlemen, and welcome to the Sonara MedTech Incorporated Q3 2022 Earnings and Business Update. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions and comments following the presentation. It is now my pleasure to turn the floor over to your host, Colin Nichols, Director of Investor Relations. Sir, the floor is yours.

Thank you, and good morning, everyone. I'd like to welcome you to Sonara MedTech's Earnings Conference Call. for the quarter ended September 30th, 2022. We issued our earnings release yesterday afternoon, and I would also like to highlight that today's deck can be found under the SEC filing section of the investor relations page of our website. This supplemental deck, as well as a copy of the earnings release and a form 10-Q for the quarter ended September 22 are available on this page. We will reference this information in our remarks today. We expect today's prepared comments from Ron Nixon, Executive Chairman, Zach Fleming, Chief Executive Officer, and Mike McNeil, Chief Financial Officer, to last approximately 15 minutes to allow time for Q&A. Certain statements in this conference call, in our press release, and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risk and uncertainties involving forward-looking statements and factors that could cause actual results to vary materially from those projected or implied by forward-looking statements, please see our most recent annual report on Form 10-K and our Form 10-Q for the quarter. Now, I'd like to turn the call over to Ron.

Thank you, Kellen, and good morning, everyone. In the third quarter of 2022, Sonera generated $13 million dollars in revenue, representing a 124% increase from the prior year period. Third quarter revenues included $3 million of Cyndia sales. The third quarter of 22 was another record quarter for Synera, as well as for our historical business before we acquired Cyndia. Additionally, it was also the first quarter during which the company generated $4 million of revenue in a single month. Company had a loss before income taxes of $3.2 million for the third quarter of 2022. The higher loss in 2022 was due to increased SG&A costs, higher R&D expenses, and higher amortization of our acquired intangibles. Mike will go into further detail, but our net loss after tax is $1.5 million for Q3. The lower net loss in 2022 is due to the recognition of a non-cash income tax benefit of $1.7 million in Q3 related to purchase accounting of the CINDIA acquisition. As previously discussed at the beginning of the third quarter, we completed our acquisition of CINDIA. So I could go into more detail shortly. During the quarter, we worked to integrate CINDIA into Scenaria's business, and we continue to see significant opportunities as well as synergies from the combination of the two companies we proved this combination's value through our previous cindia joint venture which led to the acquisition of the business subsequent to the end of the quarter we announced our partnership with infu system holdings we will discuss this later in the call but this partnership pairs scenario's product line and deep expertise in wound care with infu systems distribution and complex billing capabilities as well as our existing sales team and national footprint. In Q3, we delayed the submission of our precision healing imager 510K due to an electrical firmware issue that has now been resolved. We plan to file our 510K next month by the end of the year. Turning to our broader comprehensive wound and skin strategy, we continue to have discussions with a number of value-based companies and plan to launch this strategy in 2022. Now I'd like to have as I'm coming to discuss the quarter and .